Zhao Jiayang, vice president and senior analyst of Bbüü Capital, believes that under the pressure of the outflow of funds from Hong Kong stocks, it is difficult for technology stocks to reverse the low valuation in the short term. Biomedicine valuation is high, focus on leading enterprises. The cost of green electricity has dropped significantly, and the future may become the main force.
![Deloitte: Asian micro-multinationals are on the rise and enter a strong growth cycle over the next three years[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)